Last reviewed · How we verify
Rivastigmine 5 and 10 cm^2 patch
Rivastigmine 5 and 10 cm² patch, marketed by Novartis, is a well-established treatment in its class. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential generic competition post-patent expiry, which could erode market share and revenue.
At a glance
| Generic name | Rivastigmine 5 and 10 cm^2 patch |
|---|---|
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease (PHASE3)
- Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease (PHASE3)
- Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 (PHASE4)
- Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline (PHASE3)
- Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease (PHASE4)
- Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD) (PHASE3)
- A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivastigmine 5 and 10 cm^2 patch CI brief — competitive landscape report
- Rivastigmine 5 and 10 cm^2 patch updates RSS · CI watch RSS
- Novartis portfolio CI